Holen Sie sich die Stockscreener-App
3.29
0.60%
-0.02
Handel nachbörslich:
3.18
-0.11
-3.34%
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView
CABA Shows Promising Results in New Clinical Data - GuruFocus
CABA: Cabaletta Bio Signs Major Supply Agreement and Reports Pro - GuruFocus
Cabaletta Bio 2026 Q1 10-Q Filing: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Cabaletta Bio Unveils Promising Preconditioning-Free Rese-cel CAR-T Data and Automated Manufacturing Advances at ASGCT 2026 Annual Meeting - Minichart
Cabaletta Bio Reports Promising 2026 Q1 Results: Rese-cel CAR-T Therapy Advances, New Data & $150M Financing Highlighted - Minichart
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune (CABA) - Seeking Alpha
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Cabaletta Bio (CABA) Fairly Valued After Q1 2026? EPS -$0.39 - GuruFocus
Cabaletta Bio presents data on preconditioning-free rese-cel By Investing.com - Investing.com Australia
Cabaletta Bio Reports Encouraging RESET-PV Trial Data - TipRanks
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio presents data on preconditioning-free rese-cel - Investing.com
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - The Manila Times
Cabaletta Bio (NASDAQ: CABA) warns on going concern despite $141M cash raise - Stock Titan
Cabaletta Bio, Inc. 1Q 2026: Net loss $(43.5M), EPS $(0.39) — 10-Q Summary - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Autoimmune cell therapy push: Cabaletta raises $150M for rese-cel trials - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
U.S. Earnings Preview: Before Market Open May 13 - Moomoo
TradingKey - TradingKey
Cabaletta Bio (CABA) Eps Diluted (TTM) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
Number of shareholders of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Number of shareholders of Cabaletta Bio, Inc. – BMV:CABA - TradingView
CABA Stock Pops As $30 Target, Funding And Manufacturing Align - timothysykes.com
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta Bio Announces $150 Million Equity Offering - The Globe and Mail
Cabaletta Bio prices $150 million public offering - The Pharma Letter
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting - MyChesCo
Cabaletta Bio | 8-K: Current report - Moomoo
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy - TechStock²
CABA Reiterates by Cantor Fitzgerald -- Price Target Maintained at $30 - GuruFocus
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):